Genmab licensing deal with Revitope

Privately-held Revitope Oncology, a biotechnology company advancing a new class of precision cancer immunotherapies, has signed a license agreement providing Danish biotech Genmab (Nasdaq: GMAB) with access to Revitope's conditional TCE technology, TwoGATE.

Boston, USA-based Revitope noted that Genmab is granted exclusive rights to utilize TwoGate for multiple drug target pairs during a multi-year research period, including the option to take up to three exclusive licenses for worldwide development and commercialization of the resulting products.

TwoGATE leverages the dual antigen binding requirement of a unique split paratope that assembles on the tumor cell surface to potently engage T cells with high precision, potentially addressing key areas of unmet need in the treatment of solid tumors.